ATE530167T1 - Kombinierte dosierform mit einem cholesterinsenker, einem renin-angiotensin-hemmer und acetylsalicylsäure - Google Patents

Kombinierte dosierform mit einem cholesterinsenker, einem renin-angiotensin-hemmer und acetylsalicylsäure

Info

Publication number: ATE530167T1
Authority: AT; Austria
Prior art keywords: active agents; renin; dosage form; lowering agent; salicylic acid
Prior art date: 2001-08-28

Application number

AT02773266T

Other languages

English (en)

Inventor

Shubha Chungi

Theodore Iorio

Original Assignee

Brigham & Womens Hospital

Massachusetts College Of Pharmacy And Health Sciences

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-28

Filing date

2002-08-28

Publication date

2011-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25477337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE530167(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-28 Application filed by Brigham & Womens Hospital, Massachusetts College Of Pharmacy And Health Sciences filed Critical Brigham & Womens Hospital

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE530167T1 publication Critical patent/ATE530167T1/de

Links

BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title abstract 2
229960001138 acetylsalicylic acid Drugs 0.000 title abstract 2
239000003529 anticholesteremic agent Substances 0.000 title abstract 2
229940127226 anticholesterol agent Drugs 0.000 title abstract 2
239000002552 dosage form Substances 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
239000013543 active substance Substances 0.000 abstract 4
238000009472 formulation Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
229930003779 Vitamin B12 Natural products 0.000 abstract 1
206010000891 acute myocardial infarction Diseases 0.000 abstract 1
230000007211 cardiovascular event Effects 0.000 abstract 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
229940014144 folate Drugs 0.000 abstract 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
235000019152 folic acid Nutrition 0.000 abstract 1
239000011724 folic acid Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
230000036454 renin-angiotensin system Effects 0.000 abstract 1
201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
235000019163 vitamin B12 Nutrition 0.000 abstract 1
239000011715 vitamin B12 Substances 0.000 abstract 1
235000019158 vitamin B6 Nutrition 0.000 abstract 1
239000011726 vitamin B6 Substances 0.000 abstract 1
229940011671 vitamin b6 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT02773266T 2001-08-28 2002-08-28 Kombinierte dosierform mit einem cholesterinsenker, einem renin-angiotensin-hemmer und acetylsalicylsäure ATE530167T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/941,948 US6669955B2 (en)	2001-08-28	2001-08-28	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
PCT/US2002/027877 WO2003020243A1 (en)	2001-08-28	2002-08-28	Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin

Publications (1)

Publication Number	Publication Date
ATE530167T1 true ATE530167T1 (de)	2011-11-15

Family

ID=25477337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02773266T ATE530167T1 (de)	2001-08-28	2002-08-28	Kombinierte dosierform mit einem cholesterinsenker, einem renin-angiotensin-hemmer und acetylsalicylsäure

Country Status (13)

Country	Link
US (1)	US6669955B2 (de)
EP (1)	EP1429729B1 (de)
JP (3)	JP2005504064A (de)
KR (1)	KR20040037075A (de)
CN (2)	CN1575162A (de)
AT (1)	ATE530167T1 (de)
AU (1)	AU2002336419B2 (de)
CA (1)	CA2461958C (de)
ES (1)	ES2307463T3 (de)
IL (2)	IL160643A0 (de)
NZ (1)	NZ532014A (de)
WO (1)	WO2003020243A1 (de)
ZA (1)	ZA200402417B (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6423055B1 (en) *	1999-07-14	2002-07-23	Cardiofocus, Inc.	Phototherapeutic wave guide apparatus
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en)	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020068078A1 (en)	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2005508358A (ja) *	2001-10-25	2005-03-31	デポメド・インコーポレイテッド	胃滞留型ロサルタン投与量を用いる治療方法
MXPA04009968A (es)	2002-04-09	2004-12-13	Flamel Tech Sa	Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
EP1501546B1 (de) *	2002-05-03	2012-10-10	Hexal AG	Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
US20050182106A1 (en) *	2002-07-11	2005-08-18	Sankyo Company, Limited	Medicinal composition for mitigating blood lipid or lowering blood homocysteine
CN100341509C (zh) *	2002-07-11	2007-10-10	三共株式会社	用于改善血液中脂质或降低血液中高半胱氨酸的药物组合物
US20040115265A1 (en) *	2002-12-11	2004-06-17	Loutfy Benkerrour	Multilayered tablet containing pravastatin and aspirin and method
CA2530788C (en) *	2003-06-26	2010-02-09	Teva Pharmaceutical Industries Ltd	Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US10517883B2 (en) *	2003-06-27	2019-12-31	Zuli Holdings Ltd.	Method of treating acute myocardial infarction
US20050013863A1 (en)	2003-07-18	2005-01-20	Depomed, Inc., A Corporation Of The State Of California	Dual drug dosage forms with improved separation of drugs
EP1648418A4 (de)	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
EP1648415A4 (de)	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
CA2533292C (en)	2003-07-21	2013-12-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
NZ544784A (en) *	2003-07-28	2009-11-27	Reddys Lab Inc Dr	Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
WO2005016311A1 (en)	2003-08-11	2005-02-24	Advancis Pharmaceutical Corporation	Robust pellet
CA2535398C (en)	2003-08-12	2013-11-12	Advancis Pharmaceuticals Corporation	Antibiotic product, use and formulation thereof
EP1658034A4 (de)	2003-08-29	2011-06-22	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
US20050054731A1 (en) *	2003-09-08	2005-03-10	Franco Folli	Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005027877A1 (en)	2003-09-15	2005-03-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
US8246986B2 (en)	2003-09-26	2012-08-21	Alza Corporation	Drug coating providing high drug loading
WO2005053687A1 (en) *	2003-11-25	2005-06-16	Novartis Ag	Combination of organic compounds
EP1579862A1 (de)	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en)	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
EP1784193A4 (de) *	2004-06-28	2009-09-23	Smith Howard J & Ass Pty Ltd	Zusammensetzung und verfahren zur behandlung und prävention von atherosklerose
US8715727B2 (en)	2004-07-02	2014-05-06	Shionogi Inc.	Tablet for pulsed delivery
CA2572815A1 (en) *	2004-07-09	2006-01-19	Medicure International Inc.	Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
EP2594259A1 (de)	2004-08-04	2013-05-22	Brookwood Pharmaceuticals, Inc.	Verfahren zur Herstellung von Abgabevorrichtungen und damit erhaltene Vorrichtungen
US20060034913A1 (en) *	2004-08-13	2006-02-16	James Gaede	Multiplex drug delivery device
CN104958270A (zh) *	2004-08-25	2015-10-07	伊森舍丽斯有限公司	钾atp通道开放剂的药物制剂及其应用
US8541026B2 (en)	2004-09-24	2013-09-24	Abbvie Inc.	Sustained release formulations of opioid and nonopioid analgesics
CA2581816A1 (en) *	2004-09-27	2006-04-06	Sigmoid Biotechnologies Limited	Microcapsules comprising a methylxanthine and a corticosteroid
WO2006084560A1 (en) *	2005-02-09	2006-08-17	Unilever N.V.	Composition comprising peptide
EP1865972B1 (de) *	2005-03-23	2013-11-06	CHS Pharma, Inc.	Behandlung oder vorbeugung von krebs und präkanzerösen erkrankungen
US9757384B2 (en)	2005-04-06	2017-09-12	Essentialis, Inc.	Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
JP2008535928A (ja) *	2005-04-12	2008-09-04	シヴィダ・インコーポレイテッド	ＨＭＧＣｏＡ還元酵素インヒビターの組合せ及びその使用
US20060292225A1 (en) *	2005-06-24	2006-12-28	Felix Arthur M	Water soluble analgesic formulations and methods for production
EP1741427A1 (de) *	2005-07-06	2007-01-10	KRKA, D.D., Novo Mesto	Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
WO2007011524A1 (en) *	2005-07-14	2007-01-25	Franco Folli	Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
CN1903364B (zh) *	2005-07-26	2011-06-22	安徽省现代中药研究中心	含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物
WO2007016306A2 (en) *	2005-08-01	2007-02-08	Psivida Inc.	HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
WO2007053406A1 (en) *	2005-10-28	2007-05-10	Novartis Ag	Combinations of antihypertensive and cholesterol lowering agents
US20070112593A1 (en) *	2005-11-14	2007-05-17	Rxcera Pharmaceutical, Inc.	Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20070116756A1 (en) *	2005-11-23	2007-05-24	Dr. Reddy's Laboratories Limited	Stable pharmaceutical compositions
US8778924B2 (en)	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007068287A1 (en) *	2005-12-15	2007-06-21	Laboratoria Qualiphar	Sustained release vitamin preparation
WO2007091253A2 (en) *	2006-02-06	2007-08-16	C.T.S. Ltd.	Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels
EP1818050A1 (de) *	2006-02-10	2007-08-15	Stada Arzneimittel Ag	Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
EP1825848A3 (de) *	2006-02-10	2010-03-03	Stada Arzneimittel Ag	Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
US20070196515A1 (en) *	2006-02-22	2007-08-23	Kothari Shil C	Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome X
EP2010162A4 (de) *	2006-04-03	2013-01-09	Isa Odidi	Zusammensetzung zur abgabe eines arzneimittels
WO2007121356A2 (en) *	2006-04-13	2007-10-25	Accu-Break Technologies	Method of treatment with predictably breakable pharmaceutical tablets
WO2007120930A2 (en) *	2006-04-19	2007-10-25	Teva Pharmaceutical Industries Ltd.	Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
ES2300188B1 (es) *	2006-05-24	2009-05-01	Ferrer Internacional, S.A.	Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
CA2654529A1 (en) *	2006-07-06	2008-01-10	Teva Pharmaceutical Industries Ltd.	Compositions with controlled pharmacokinetics
US20080026053A1 (en) *	2006-07-28	2008-01-31	Sovereign Pharmaceuticals, Ltd.	Capsule containing granular pharmaceutical compositions
CN101534798B (zh) *	2006-10-30	2012-02-15	韩诺生物制约株式会社	包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
US8394845B2 (en)	2006-10-30	2013-03-12	Hanall Biopharma Co., Ltd.	Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
US8642083B2 (en)	2006-10-30	2014-02-04	Hanall Biopharma Co., Ltd.	Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
EP1920785A1 (de)	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
WO2008068217A2 (en) *	2006-12-04	2008-06-12	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
KR100870396B1 (ko) *	2006-12-07	2008-11-25	보령제약 주식회사	심혈관계 질환 치료용 경구투여제제
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
JP5467870B2 (ja) *	2007-02-09	2014-04-09	アルファファームピーティーワイリミテッド	異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
WO2008109462A2 (en) *	2007-03-02	2008-09-12	Farnam Companies, Inc.	Sustained release pellets comprising wax-like material
EP2061440A2 (de)	2007-04-04	2009-05-27	Sigmoid Pharma Limited	Pharmazeutische tacrolimus-zusammensetzung
ES2963291T3 (es)	2007-04-26	2024-03-26	Sublimity Therapeutics Ltd	Fabricación de múltiples minicápsulas
WO2009022821A2 (en) *	2007-08-13	2009-02-19	Hanall Pharmaceutical Company. Ltd	Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090082315A1 (en) *	2007-09-05	2009-03-26	Raif Tawakol	Compositions and Methods for Controlling Cholesterol Levels
SI2200588T1 (sl)	2007-09-25	2019-08-30	Solubest Ltd.	Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
WO2009045795A2 (en) *	2007-09-28	2009-04-09	Novartis Ag	Galenical formulations of aliskiren and valsartan
EP2070520A1 (de) *	2007-12-11	2009-06-17	LEK Pharmaceuticals D.D.	Pharmazeutische Zusammensetzung mit mindestens einem Wirkstoff und einem in einem sauren Medium quellenden Bindemittel
CA2709712C (en)	2007-12-20	2016-05-10	Surmodics Pharmaceuticals, Inc.	Process for preparing microparticles having a low residual solvent volume
MX344778B (es) *	2008-01-25	2017-01-06	Duo-Ge	Combinacion de medicamentos orales unidos por una envoltura.
CN101980701A (zh) *	2008-03-28	2011-02-23	菲尔若国际公司	用于预防心血管疾病的胶囊
CN102088965B (zh) *	2008-05-13	2013-05-08	根梅迪卡治疗公司	水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
CN101590240B (zh) *	2008-05-30	2012-04-25	北京奥萨医药研究中心有限公司	含血管紧张素ⅱ受体拮抗剂、他汀和叶酸的组合物及用途
GB2460915B (en)	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2204170A1 (de) *	2008-12-01	2010-07-07	LEK Pharmaceuticals D.D.	Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
US9789187B2 (en) *	2009-02-11	2017-10-17	Cadila Pharmaceuticals Limited	Stable pharmaceutical composition for atherosclerosis
JP2012520342A (ja) *	2009-03-16	2012-09-06	ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ	代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CN102421424A (zh) *	2009-03-16	2012-04-18	根梅迪卡治疗公司	用于治疗代谢性疾病的组合疗法
ES2530049T3 (es)	2009-05-18	2015-02-26	Sigmoid Pharma Limited	Composición que comprende gotas de aceite
US20120064161A1 (en) *	2009-05-18	2012-03-15	Dr. Reddy's Laboratories, Inc.	Modified release niacin pharmaceutical formulations
BR112012002963A2 (pt)	2009-08-12	2017-10-24	Sigmoid Pharma Ltd	composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
JP5827952B2 (ja) *	2009-10-09	2015-12-02	ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎＰｈａｒｍ．Ｃｏ．Ｌｔｄ．	速効性と持続性を同時に有する薬剤学的組成物
JP4899224B2 (ja) *	2010-05-11	2012-03-21	春三小林	動脈硬化改善剤
TR201005325A2 (tr)	2010-06-30	2012-01-23	Bi̇lgi̇ç Mahmut	Atorvastatin ve aspirin içeren farmasötik formülasyonlar
WO2012028966A2 (en) *	2010-07-21	2012-03-08	Nucitec S.A. De C.V.	Combination dosage compositions comprising a cholesterol-lowering agent, a renin-angiotensin system inhibitor, an antioxidant agent and an antiplatelet agent for treatment and prevention of cardiovascular disease
US8470365B2 (en) *	2010-07-29	2013-06-25	Taiwan Biotech Co., Ltd.	Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
JP6106359B2 (ja) *	2010-12-13	2017-03-29	第一三共ヘルスケア株式会社	ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
US8466197B2 (en)	2010-12-14	2013-06-18	Genmedica Therapeutics Sl	Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
ES2755075T3 (es) *	2011-05-05	2020-04-21	Hennig Arzneimittel Gmbh&Co Kg	Forma farmacológica para la liberación dirigida de principios activos
KR101840086B1 (ko) *	2011-07-15	2018-03-19	액세스 비지니스 그룹 인터내셔날 엘엘씨	다중카로티노이드 비들렛 및 관련 방법
EP3167876B1 (de) *	2012-03-15	2021-09-08	Boehringer Ingelheim Vetmedica GmbH	Pharmazeutische tablettenformulierung für den veterinärmedizinischen sektor, verfahren zur herstellung und verwendung davon
JP6160263B2 (ja) *	2012-06-07	2017-07-12	大正製薬株式会社	ロキソプロフェン含有医薬組成物
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
US9993427B2 (en)	2013-03-14	2018-06-12	Biorest Ltd.	Liposome formulation and manufacture
EP2810644A1 (de)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
ES2524645B1 (es) *	2013-06-06	2015-12-02	Ferrer Internacional, S.A.	Formulación oral para el tratamiento de enfermedades cardiovasculares
DK3021832T3 (da)	2013-07-19	2021-05-25	Boehringer Ingelheim Vetmedica Gmbh	Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
ES2593210T3 (es)	2013-12-04	2016-12-07	Boehringer Ingelheim Vetmedica Gmbh	Composiciones farmacéuticas mejoradas de pimobendán
CN104001176B (zh) *	2014-06-11	2016-06-22	深圳奥萨医药有限公司	血小板adp受体拮抗剂和b族维生素的药物组合物
EA036036B1 (ru)	2014-11-07	2020-09-16	Сигмойд Фарма Лимитед	Композиции, содержащие циклоспорин
JP6709226B2 (ja)	2014-11-14	2020-06-10	エッセンシャライズインコーポレイテッド	プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法
GB2533669B (en) *	2014-12-23	2016-12-14	Innovate Pharmaceuticals Ltd	Salicylate compound composition
BE1023011B1 (nl) *	2015-08-05	2016-11-04	Nordic Specialty Pharma Bvba	Acetylsalicylzuur tablet met onmiddellijke afgifte
US10537570B2 (en)	2016-04-06	2020-01-21	Boehringer Ingelheim Vetmedica Gmbh	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
WO2018124236A1 (ja) *	2016-12-27	2018-07-05	国立大学法人大阪大学	難治性心疾患治療用医薬組成物
WO2019109415A1 (zh) *	2017-12-04	2019-06-13	清华大学	一种靶向降解hmgcr的化合物及其应用
MX2021012728A (es)	2019-04-17	2022-01-24	Cardiopharma Inc	Combinación de dosis fija de antihipertensivo y reductor de colesterol y método de fabricación.
KR20240029726A (ko) *	2021-07-23	2024-03-06	프로캡스 에스에이	연질 쉘 젤라틴 캡슐

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2016467A1 (en) *	1989-06-05	1990-12-05	Martin Eisman	Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2040865C (en)	1990-05-15	2002-07-23	James L. Bergey	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en)	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en)	1990-05-31	1992-08-18	E. R. Squibb & Sons, Inc.	Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) *	1990-06-11	1997-04-22	Bristol-Myers Squibb Company	Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5157025A (en)	1991-04-01	1992-10-20	E. R. Squibb & Sons, Inc.	Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
EP0622078B1 (de)	1992-01-14	1999-09-01	Hisamitsu Pharmaceutical Co., Inc.	Cholesterinspiegelsenkendes mittel
WO1998011896A1 (en) *	1996-09-18	1998-03-26	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) *	1996-09-18	2001-06-26	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardiovascular disease
US6235311B1 (en) *	1998-03-18	2001-05-22	Bristol-Myers Squibb Company	Pharmaceutical composition containing a combination of a statin and aspirin and method
WO1999065500A1 (en) *	1998-06-17	1999-12-23	Bristol-Myers Squibb Company	Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
HUP0203326A3 (en)	1999-08-30	2003-04-28	Sanofi Aventis Deutschland	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
ATE326240T2 (de)	2000-04-10	2006-06-15	Nicholas John Wald	Zusammensetzung zur prävention kardiovaskulärer erkrankungen
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

2001
- 2001-08-28 US US09/941,948 patent/US6669955B2/en not_active Expired - Lifetime
2002
- 2002-08-28 NZ NZ532014A patent/NZ532014A/en not_active IP Right Cessation
- 2002-08-28 WO PCT/US2002/027877 patent/WO2003020243A1/en not_active Ceased
- 2002-08-28 AT AT02773266T patent/ATE530167T1/de not_active IP Right Cessation
- 2002-08-28 CN CNA028213513A patent/CN1575162A/zh active Pending
- 2002-08-28 EP EP02773266A patent/EP1429729B1/de not_active Expired - Lifetime
- 2002-08-28 IL IL16064302A patent/IL160643A0/xx unknown
- 2002-08-28 JP JP2003524552A patent/JP2005504064A/ja not_active Withdrawn
- 2002-08-28 KR KR10-2004-7002962A patent/KR20040037075A/ko not_active Ceased
- 2002-08-28 AU AU2002336419A patent/AU2002336419B2/en not_active Expired
- 2002-08-28 CN CN200910148802A patent/CN101642459A/zh active Pending
- 2002-08-28 ES ES02773266T patent/ES2307463T3/es not_active Expired - Lifetime
- 2002-08-28 CA CA2461958A patent/CA2461958C/en not_active Expired - Lifetime
2004
- 2004-02-26 IL IL160643A patent/IL160643A/en active IP Right Grant
- 2004-03-26 ZA ZA2004/02417A patent/ZA200402417B/en unknown
2009
- 2009-08-06 JP JP2009183888A patent/JP2009256381A/ja active Pending
2012
- 2012-09-04 JP JP2012194171A patent/JP2013006857A/ja active Pending

Also Published As

Publication number	Publication date
EP1429729A4 (de)	2007-07-04
US20030068366A1 (en)	2003-04-10
JP2005504064A (ja)	2005-02-10
US6669955B2 (en)	2003-12-30
ES2307463T1 (es)	2008-12-01
WO2003020243A1 (en)	2003-03-13
NZ532014A (en)	2005-12-23
IL160643A (en)	2010-02-17
CN1575162A (zh)	2005-02-02
EP1429729B1 (de)	2011-10-26
AU2002336419B2 (en)	2007-07-19
CN101642459A (zh)	2010-02-10
ES2307463T3 (es)	2012-03-12
CA2461958A1 (en)	2003-03-13
IL160643A0 (en)	2004-07-25
EP1429729A1 (de)	2004-06-23
CA2461958C (en)	2010-05-11
JP2009256381A (ja)	2009-11-05
KR20040037075A (ko)	2004-05-04
ZA200402417B (en)	2005-06-29
JP2013006857A (ja)	2013-01-10

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
IL160643A0 (en)	2004-07-25	Combination dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor, and aspirin
Black et al.	1997	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
EE200200086A (et)	2003-04-15	Reniin-angiotensiini süsteemi inhibiitori kasutamine, kombineeritud produkt ja meetod kardiovaskulaarsete haigusjuhtude ärahoidmiseks
BRPI0412557A (pt)	2006-09-19	forma de dosagem farmacêutica de eventos cardiovasculares
ATE356612T1 (de)	2007-04-15	Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
WO2003039519A3 (es)	2004-03-25	Forma de dosificación de liberación controlada dual
WO2002011711A3 (en)	2003-02-27	Formulations of mometasone and a bronchodilator for pulmonary administration
DK1239857T3 (da)	2006-07-31	Dual-release-præparater af en cyclooxygenase-2-hæmmer
ATE509616T1 (de)	2011-06-15	Topische pharmazeutische und/oder cosmetische dosierungssysteme
NO962841D0 (no)	1996-07-05	Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
IL166761A (en)	2010-12-30	Use of cgrp antagonist compounds for the manufacture of medicaments for treating psoriasis
TR199800631A2 (xx)	1998-10-21	Ecza form�lasyonu.
Roenigk Jr	1999	Acitretin combination therapy
FR2878161B1 (fr)	2008-10-31	Forme medicamenteuse orale, solide et concue pour eviter le mesusage
ATE247953T1 (de)	2003-09-15	Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
FR2878158B1 (fr)	2009-01-16	Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
WO2004056320A3 (en)	2004-09-23	Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
AR035946A1 (es)	2004-07-28	Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
Marrs	2010	Spironolactone management of resistant hypertension
TNSN07203A1 (en)	2008-11-21	Pharmaceutical compositions for the treatment of cellulite
PT1656131E (pt)	2011-06-07	Utilização de betaína para tratar claudicação intermitente
CA2385755A1 (en)	2001-04-05	Prevention of colorectal cancer
CA2394471A1 (en)	2001-07-05	External preparation for treating pruritus
DK1492539T3 (da)	2006-10-30	Statin-terapi til forögelse af kognitiv funktion
BG108144A (en)	2004-09-30	New use